Search Articles — Sudonull

https://sudonull.com/algorithmic-social-lifts-in-it-how-platforms-change-careers

Analysis of the transformation of career trajectories under digital platforms. Learn how to achieve autonomy in the algorithmic society.

https://sudonull.com/career-ops-automation-of-it-hiring-on-claude-code

Analysis of the Career-Ops system for scraping vacancies, adapting resumes and interview preparation. Skills for Claude Code, batch processing, risks. Instructions for middle/senior dev. Learn how to set it up.

https://sudonull.com/how-to-start-an-it-career-in-2025-beginner-s-guide

Learn how to break into IT in 2025 with practical steps. From building a portfolio to landing your first job in small companies. Start your tech career today.

https://sudonull.com/how-to-start-an-it-career-beginner-s-guide-to-success

Discover practical steps to enter the IT industry. Learn how to validate interest, network effectively, and build cognitive endurance without wasting money.

https://sudonull.com/caron-ˇ-disappeared-from-ios-iphone-lockout-with-czech-password

iOS 26.4 update removed caron (ˇ) from the lock screen keyboard, blocking access to iPhone. Technical details, bypass attempts, and risks for custom passwords. Learn how to avoid data loss.

https://ymaho.com/dual-action-car-t-100-remission-in-myeloma-at-isct-2026

ISCT 2026 data analysis: CAR-T therapy TPST-2003 showed complete response in all naive patients. Learn why this is a breakthrough, not an illusion, and what risks are hidden.

https://ymaho.com/car-t-therapy-hiv-years-of-remission-after-infusion

DUET-2 data: CAR-T cells keep HIV in remission for over 2 years without ART. Functional cure already a reality? Learn about the breakthrough in HIV treatment.

https://ymaho.com/car-t-therapy-for-ovarian-cancer-lira-cel-and-28-months-of-life

Updated Phase I data: CAR-T lira-cel showed 28-month survival in ovarian cancer. Learn why this is a breakthrough in solid tumor treatment.

https://ymaho.com/next-generation-car-t-tumor-neurobiology-and-brain-cancer-treatment

Scientists propose considering neurotransmitters for CAR-T cells in glioblastoma. A new approach to brain cancer therapy. Learn more.

https://ymaho.com/car-nk-therapy-ab-201-for-esophageal-cancer-efficacy-analysis

Expert analysis of CAR-NK therapy AB-201 for HER2-positive gastric and esophageal cancer. Why this is not a breakthrough? Risks, data, and prospects. Read.

https://ymaho.com/car-t-therapy-for-lupus-fda-approval-2026

Analysis of FDA approval of the first CAR-T cell therapy for severe lupus. Key players, forecasts, and hidden risks. Find out who is leading the race.

https://ymaho.com/universal-car-t-therapy-fda-allows-trials-for-autoimmune-diseases

FDA approved clinical trials of allogeneic CAR-T cell therapy QT-019C for lupus and scleroderma. Savings up to $100 billion, no chemotherapy. Learn about the breakthrough.

https://ymaho.com/car-t-therapy-against-aging-elimination-of-senescent-cells

An international consortium has developed CAR-T for selective elimination of senescent cells. Learn how uPAR CAR-T technology fights age-related diseases and fibrosis.

https://ymaho.com/car-t-therapy-for-lupus-100-remission-in-a-small-cohort

German rheumatologists achieved 100% remission in lupus with CAR-T. Four-year data, immune reset mechanism, and forecasts. Read.

https://ymaho.com/cardiologist-topol-debunks-myths-of-the-anti-aging-industry

Eric Topol proved: there are no longevity genes, and the $85 billion anti-aging market is overvalued. Find out why lifestyle and AI prevention are more important than peptides and cryochambers.

WhatsApp Web

https://web.whatsapp.com/

Log in to WhatsApp Web for simple, reliable and private messaging on your desktop. Send and receive messages and files with …